NIKKEI 225
26,926.50 +710.71 (+2.71%) HANG SENG
17,079.51 -143.29 (-0.83%) CRUDE OIL
83.91 +0.28 (+0.33%) GOLD FUTURES
1,705.10 +3.10 (+0.18%) DOW
29,490.89 +765.38 (+2.66%) BTC-GBP
17,278.00 +184.69 (+1.08%)
AB Science S.A. (ABSCF)
- Globe Newswire
AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION FOR THE FIRST HALF OF 2022 AND THE KEY EVENTS OF THE PERIOD Clinical development Authorization by Health Canada in February 2022 to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) under the Notice of Compliance with Conditions (NOC/c) policy and formal start of the review in May 2022. Health Canada has a target of 200 calendar days maximum to review the applicationFiling for conditional M
- Globe Newswire
AB Science - Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19
PRESS RELEASE POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING BOARD TO CONTINUE THE PHASE 2 STUDY EVALUATING ANTIVIRAL ACTIVITY OF MASITINIB IN COVID-19 Paris, 14 September 2022, 6.15pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced continuation of the Phase 2 study evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB). This randomized (1:1), do
- Globe Newswire
AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS
PRESS RELEASE AB SCIENCE ANNOUNCES FILING OF MARKETING AUTHORIZATION APPLICATION FOR ALSITEK IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND ITS VALIDATION BY THE EUROPEAN MEDICINES AGENCY (EMA) Paris, 24 August 2022, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS). This app
